Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F List

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Blood Cancer Journal|July 26, 2012
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutationC Sugimori, E Padron, G Caceres, et al.
Leukemia|October 4, 2012
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndromeL Sokol, L Cripe, H Kantarjian, et al.
Leukemia|August 21, 2010
Novel homo- and hemizygous mutations in EZH2 in myeloid malignanciesH Makishima, A M Jankowska, R V Tiu, et al.
Leukemia|March 15, 2013
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignanciesS N Khan, A M Jankowska, R Mahfouz, et al.
Blood Cancer Journal|August 1, 2015
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategiesE Padron, G Garcia-Manero, M M Patnaik, et al.
Blood Cancer Journal|March 14, 2015
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesK L McGraw, L M Zhang, D E Rollison, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Blood Cancer Journal|July 26, 2012
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutationC Sugimori, E Padron, G Caceres, et al.
Leukemia|October 4, 2012
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndromeL Sokol, L Cripe, H Kantarjian, et al.
Leukemia|August 21, 2010
Novel homo- and hemizygous mutations in EZH2 in myeloid malignanciesH Makishima, A M Jankowska, R V Tiu, et al.
Leukemia|March 15, 2013
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignanciesS N Khan, A M Jankowska, R Mahfouz, et al.
Blood Cancer Journal|August 1, 2015
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategiesE Padron, G Garcia-Manero, M M Patnaik, et al.
Blood Cancer Journal|March 14, 2015
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesK L McGraw, L M Zhang, D E Rollison, et al.
Pageof 10